BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 17015900)

  • 1. PET/CT in lymphoma: prospective study of enhanced full-dose PET/CT versus unenhanced low-dose PET/CT.
    Rodríguez-Vigil B; Gómez-León N; Pinilla I; Hernández-Maraver D; Coya J; Martín-Curto L; Madero R
    J Nucl Med; 2006 Oct; 47(10):1643-8. PubMed ID: 17015900
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Non-Hodgkin's lymphoma staging: a prospective study of the value of positron emission tomography/computed tomography (PET/CT) versus PET and CT].
    Rodríguez-Vigil Junco B; Gómez León N; Pinilla Fernández I; del Campo L; Hernández Maraver D; Coya J
    Med Clin (Barc); 2011 Oct; 137(9):383-9. PubMed ID: 21703647
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diagnostic value of CT, PET and combined PET/CT performed with low-dose unenhanced CT and full-dose enhanced CT in the initial staging of lymphoma.
    Pinilla I; Gómez-León N; Del Campo-Del Val L; Hernandez-Maraver D; Rodríguez-Vigil B; Jover-Díaz R; Coya J
    Q J Nucl Med Mol Imaging; 2011 Oct; 55(5):567-75. PubMed ID: 21150860
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Non-Hodgkin lymphoma and Hodgkin disease: coregistered FDG PET and CT at staging and restaging--do we need contrast-enhanced CT?
    Schaefer NG; Hany TF; Taverna C; Seifert B; Stumpe KD; von Schulthess GK; Goerres GW
    Radiology; 2004 Sep; 232(3):823-9. PubMed ID: 15273335
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Can full-dose contrast-enhanced CT be omitted from an FDG-PET/CT staging examination in newly diagnosed FDG-avid lymphoma?
    van Hamersvelt HP; Kwee TC; Fijnheer R; Beek FJ; de Klerk JM; Nievelstein RA
    J Comput Assist Tomogr; 2014; 38(4):620-5. PubMed ID: 24681861
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fluorine-18 fluorodeoxyglucose PET-CT for extranodal staging of non-Hodgkin and Hodgkin lymphoma.
    Ömür Ö; Baran Y; Oral A; Ceylan Y
    Diagn Interv Radiol; 2014; 20(2):185-92. PubMed ID: 24412817
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Positron emission tomography/computed tomography: diagnostic accuracy in lymphoma.
    Hernandez-Maraver D; Hernandez-Navarro F; Gomez-Leon N; Coya J; Rodriguez-Vigil B; Madero R; Pinilla I; Martin-Curto LM
    Br J Haematol; 2006 Nov; 135(3):293-302. PubMed ID: 17032175
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of PET/MRI With PET/CT in the Evaluation of Disease Status in Lymphoma.
    Afaq A; Fraioli F; Sidhu H; Wan S; Punwani S; Chen SH; Akin O; Linch D; Ardeshna K; Lambert J; Miles K; Groves A; Kayani I
    Clin Nucl Med; 2017 Jan; 42(1):e1-e7. PubMed ID: 27607161
    [TBL] [Abstract][Full Text] [Related]  

  • 9. FDG-PET in the detection of bone marrow disease in Hodgkin's disease and aggressive non-Hodgkin's lymphoma and its impact on clinical management.
    Pelosi E; Penna D; Deandreis D; Chiappella A; Skanjeti A; Vitolo U; Bisi G
    Q J Nucl Med Mol Imaging; 2008 Mar; 52(1):9-16. PubMed ID: 18235420
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of 18F-FDG PET and 18F-FDG PET/CT in the evaluation of pediatric Hodgkin's lymphoma and non-Hodgkin's lymphoma.
    Qiu L; Chen Y; Wu J
    Hell J Nucl Med; 2013; 16(3):230-6. PubMed ID: 24137577
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Initial staging of Hodgkin's disease: role of contrast-enhanced 18F FDG PET/CT.
    Chiaravalloti A; Danieli R; Caracciolo CR; Travascio L; Cantonetti M; Gallamini A; Guazzaroni M; Orlacchio A; Simonetti G; Schillaci O
    Medicine (Baltimore); 2014 Aug; 93(8):e50. PubMed ID: 25121354
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pediatric and adolescent lymphoma: comparison of whole-body STIR half-Fourier RARE MR imaging with an enhanced PET/CT reference for initial staging.
    Punwani S; Taylor SA; Bainbridge A; Prakash V; Bandula S; De Vita E; Olsen OE; Hain SF; Stevens N; Daw S; Shankar A; Bomanji JB; Humphries PD
    Radiology; 2010 Apr; 255(1):182-90. PubMed ID: 20308456
    [TBL] [Abstract][Full Text] [Related]  

  • 13. FDG PET/CT of extranodal involvement in non-Hodgkin lymphoma and Hodgkin disease.
    Paes FM; Kalkanis DG; Sideras PA; Serafini AN
    Radiographics; 2010 Jan; 30(1):269-91. PubMed ID: 20083598
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nodal status of malignant lymphoma in pelvic and retroperitoneal lymphatic pathways: comparison of integrated PET/CT with or without contrast enhancement.
    Morimoto T; Tateishi U; Maeda T; Arai Y; Nakajima Y; Edmund Kim E
    Eur J Radiol; 2008 Sep; 67(3):508-13. PubMed ID: 17904324
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fluorine-18 fluorodeoxyglucose PET/CT patterns of extranodal involvement in patients with Non-Hodgkin lymphoma and Hodgkin's disease.
    Even-Sapir E; Lievshitz G; Perry C; Herishanu Y; Lerman H; Metser U
    Radiol Clin North Am; 2007 Jul; 45(4):697-709, vii. PubMed ID: 17706534
    [TBL] [Abstract][Full Text] [Related]  

  • 16. F-18 FDG-PET imaging and correlation with CT in staging and follow-up of pediatric lymphomas.
    Hernandez-Pampaloni M; Takalkar A; Yu JQ; Zhuang H; Alavi A
    Pediatr Radiol; 2006 Jun; 36(6):524-31. PubMed ID: 16622665
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lymphoma: role of whole-body 2-deoxy-2-[F-18]fluoro-D-glucose (FDG) PET in nodal staging.
    Moog F; Bangerter M; Diederichs CG; Guhlmann A; Kotzerke J; Merkle E; Kolokythas O; Herrmann F; Reske SN
    Radiology; 1997 Jun; 203(3):795-800. PubMed ID: 9169707
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Whole-body FDG-PET imaging for staging of Hodgkin's disease and lymphoma.
    Hoh CK; Glaspy J; Rosen P; Dahlbom M; Lee SJ; Kunkel L; Hawkin RA; Maddahi J; Phelps ME
    J Nucl Med; 1997 Mar; 38(3):343-8. PubMed ID: 9074514
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of diffusion-weighted MRI for pretherapeutic assessment and staging of lymphoma: results of a prospective study in 140 patients.
    Mayerhoefer ME; Karanikas G; Kletter K; Prosch H; Kiesewetter B; Skrabs C; Porpaczy E; Weber M; Pinker-Domenig K; Berzaczy D; Hoffmann M; Sillaber C; Jaeger U; Müllauer L; Simonitsch-Klupp I; Dolak W; Gaiger A; Ubl P; Lukas J; Raderer M
    Clin Cancer Res; 2014 Jun; 20(11):2984-93. PubMed ID: 24696320
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Utility of fluorodeoxyglucose-PET imaging in the management of patients with Hodgkin's and non-Hodgkin's lymphomas.
    Kumar R; Maillard I; Schuster SJ; Alavi A
    Radiol Clin North Am; 2004 Nov; 42(6):1083-100. PubMed ID: 15488559
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.